India, Sept. 11 -- Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark), today announced the launch of RYALTRIS(R) Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older.The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) earlier this year.The launch reflects Glenmark's continued commitment to advancing its respiratory innovation journey and reinforces the Company's continued progress in expanding access to differentiated therapies across global markets.Allergic rhinitis is a highly prevalent chronic condition...